Steelhead Partners is an investment fund managing more than $721 thousand ran by Brent Binge. There is currently 1 company in Mr. Binge’s portfolio. The largest and only investment include Alnylam Pharmaceuticals Inc worth $721 thousand.
As of 7th November 2022, Steelhead Partners’s top holding is 3,600 shares of Alnylam Pharmaceuticals Inc currently worth over $721 thousand and making up 100.0% of the portfolio value.
Relative to the number of outstanding shares of Alnylam Pharmaceuticals Inc, Steelhead Partners owns more than approximately 0.1% of the company.
Currently, Steelhead Partners's portfolio is worth at least $721 thousand. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Steelhead Partners office and employees reside in Seattle, Washington. According to the last 13-F report filed with the SEC, Brent Binge serves as the General Counsel and Chief Compliance Officer at Steelhead Partners.
In the most recent 13F filing, Steelhead Partners revealed that it had opened a new position in
Alnylam Pharmaceuticals Inc and bought 3,600 shares worth $721 thousand.
On the other hand, there are companies that Steelhead Partners is getting rid of from its portfolio.
Steelhead Partners closed its position in Precigen Inc on 14th November 2022.
It sold the previously owned 50,000 shares for $106 thousand.
The two most similar investment funds to Steelhead Partners are Kirkwood Investment Management L.P. and Eii Capital Management, Inc. They manage $683 thousand and $774 thousand respectively.
Steelhead Partners’s portfolio is diversified across 1 sector.
Currently, their heaviest sector is Health Care — making up 100.0% of
the total portfolio value.
The fund focuses on investments in the United States as
100.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
100% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $25.9 billion.
These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc |
Opened
3,600
|
$721,000 | 100.00% |
| Precigen Inc |
Closed
50,000
|
$106,000 | |
| No transactions found | |||
| Showing first 500 out of 2 holdings | |||